Small Molecules
12 November 2013
Ligand Initiates Phase 1 Trial with Glucagon Receptor Antagonist for Type 2 Diabetes12 November 2013
Shield Therapeutics Files Investigational New Drug Application for ST10 for the Treatment of Iron Deficiency in Chronic Kidney Disease12 November 2013
GSK announces top-line results from pivotal Phase III study of darapladib in chronic coronary heart disease11 November 2013
AB Science: Masitinib successfully passes futility analysis in pivotal clinical study in Mastocytosis11 November 2013
Genkyotex NOX Inhibitor GKT137831 Successfully Shown to Halt Diabetic Kidney Disease11 November 2013
Revalesio Initiates Phase IIa Study of RNS60 in Multiple Sclerosis at University Hospital Zurich11 November 2013
Zalicus Reports Results from Phase 2 Clinical Trials of Z160 in Chronic Neuropathic Pain11 November 2013
ZS Pharma Announces Positive Top-Line Results of Phase 3 Trial of ZS-9 in Patients with Hyperkalemia11 November 2013
GW Pharmaceuticals Commences Phase 1b/2a Clinical Trial for the Treatment of Glioblastoma Multiforme (GBM)8 November 2013
Pfizer Announces Top-Line Results Of Phase 3B/4 Study Of RAPAMUNE® (sirolimus) In Renal Transplant Recipients8 November 2013
Cerecor Announces Initiation of Phase 2 Study for CERC-301, an Oral Rapid-acting Antidepressant Candidate8 November 2013
BioCryst Initiates OPuS-1: a Phase 2a Clinical Trial of BCX4161 in Patients with Hereditary Angioedema6 November 2013
Aclaris Therapeutics Initiates IND-Directed Program for A-101 for the Treatment of Seborrheic Keratosis, Common Type of Skin Tumor6 November 2013
Aerpio Therapeutics Announces Successful Completion of Phase 1b/2a Trial in Diabetic Macular Edema and $9 Million Series A Extension6 November 2013
Curis Reports Third Quarter 2013 Financial Results and Provides CUDC-427 Development Update5 November 2013
Serodus Enrolls First Patient in SER100 Phase IIa Isolated Systolic Hypertension Clinical Study5 November 2013
Aeterna Zentaris Submits New Drug Application to FDA for Macimorelin Acetate (AEZS-130) for Evaluation of AGHD5 November 2013
Trophos completes pivotal phase II/III study of olesoxime in Spinal Muscular Atrophy (SMA)5 November 2013
Positive Top-line Results Shown for Vyvanse® (lisdexamfetamine dimesylate) Capsules (CII) in Adults with Binge Eating Disorder5 November 2013
Reviva Pharmaceuticals Announces Successful End-of-Phase 2 Meeting With FDA for RP5065 November 2013
Genkyotex Initiates Multinational Phase II Study with First in Class NOX Inhibitor GKT137831 in Diabetic Nephropathy Patients5 November 2013
Aclidinium and formoterol fixed dose combination for COPD submitted for registration in EuropeNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports